OOIR: Observatory of International Research

Papers

(The H4-Index of Neuropharmacology is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease	388
Mechanisms of action of currently used antiseizure drugs	248
Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology	170
Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration	142
Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species	131
Inflammation and reactive oxygen species as disease modifiers in epilepsy	113
Amygdala, neuropeptides, and chronic pain-related affective behaviors	105
Central 5-HT receptors and their function; present and future	104
The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments	87
Pharmacoresistance – Epidemiology, mechanisms, and impact on epilepsy treatment	85
The hypocretin (orexin) system: from a neural circuitry perspective	79
Modulating neuroinflammation and oxidative stress to prevent epilepsy and improve outcomes after traumatic brain injury	77
Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms	74
Social vulnerabilities for substance use: Stressors, socially toxic environments, and discrimination and racism	74
Endogenous opioid peptides in the descending pain modulatory circuit	73
Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model	72
Disease-modifying therapies in amyotrophic lateral sclerosis	71
Nicotinic acetylcholine receptors: Conventional and unconventional ligands and signaling	68
Biomarkers for epileptogenesis and its treatment	68
Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator	65
Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction	64
Sex differences in vulnerability to addiction	62
Targeting BDNF/TrkB pathways for preventing or suppressing epilepsy	60
α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future	59
Progress in nicotinic receptor structural biology	57

Acetylcholinesterase inhibitors (nerve agents) as weapons of mass destruction: History, mechanisms of action, and medical countermeasures	57
Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics	57
Optogenetic and chemogenetic therapies for epilepsy	55
Different roles of distinct serotonergic pathways in anxiety-like behavior, antidepressant-like, and anti-impulsive effects	54
Better living through understanding the insula: Why subregions can make all the difference	53
Urolithin A promotes mitophagy and suppresses NLRP3 inflammasome activation in lipopolysaccharide-induced BV2 microglial cells and MPTP-induced Parkinson's disease model	53
The cannabinoid system and microglia in health and disease	49
The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy	49
Tau immunotherapies: Lessons learned, current status and future considerations	48
Insight and medication adherence in schizophrenia: An analysis of the CATIE trial	47
Astrocyte control of glutamatergic activity: Downstream effects on serotonergic function and emotional behavior	46
Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics	46
NMDA receptors and synaptic plasticity in the anterior cingulate cortex	45
Impulsivity traits and neurocognitive mechanisms conferring vulnerability to substance use disorders	44
Median raphe serotonin neurons promote anxiety-like behavior via inputs to the dorsal hippocampus	43
Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research	43
Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics	41